Skip to content
type1.science

Omnipod 6 (pump)

Insulet

Insulet's next-generation tubeless patch pump, intended to launch in 2027 as the successor to Omnipod 5. It keeps the same ~200-unit, ~3-day Pod but adds a new adaptive-learning algorithm, a lower 100 mg/dL target, and one "universal" Pod that works across Dexcom and FreeStyle Libre sensors. Still a hybrid closed-loop (you announce meals). Not yet FDA-cleared — features and timing may change.

On the horizonEarly evidencepumptubelesspatchphone-control

The scorecard

Interoperability78

A single "universal" Pod is designed to work across Dexcom and FreeStyle Libre sensors and future CGMs, broadening compatibility — but it remains a closed commercial system, not open to DIY loops.[1]

Reliability70

Pivotal STRIVE data show non-inferior hypoglycemia and zero DKA/severe hypos, and it inherits Insulet's mature Pod platform — but it is pre-market with no real-world track record yet.[4]

Form factor92

Keeps the fully tubeless, waterproof patch form factor of Omnipod 5 — the same shape and size — so it retains the category's defining no-tubing advantage.[3]

Phone control86

Expected to continue full smartphone bolusing via a redesigned app, with a separate controller still offered, consistent with Omnipod 5.[1]

Capacity58

Expected to keep the ~200-unit reservoir and ~3-day (72 h) single-use Pod wear of Omnipod 5; larger capacity and longer wear are deferred to a later redesign beyond 2028.[3]

Access & cost40

Not yet available anywhere: a 510(k) filing is planned and a 2027 launch is targeted, so access, regional rollout and Pod pricing are all unconfirmed.[2]

Editor’s take

An evolution, not a revolution — and that's the point. By keeping the proven Pod and concentrating the upgrade in software (a learning algorithm, lower target) and one CGM-agnostic Pod, Insulet can ship faster and let a single patch follow whichever sensor you choose. The bigger redesign — more insulin, longer wear, fully closed loop — is still years out. Treat every spec here as provisional until FDA clearance.

The full picture

The Omnipod 6 is the next-generation tubeless patch pump on Insulet's public roadmap, announced at the company's November 2025 Investor Day and intended to launch in 2027 as the successor to Omnipod 5.1 It is not yet approved or on sale anywhere — everything below is drawn from Insulet's stated plans and early trial data, and the specifics could change before clearance.2

Form factor: still a tubeless patch. Omnipod 6 keeps the same waterproof, tubeless patch form factor as Omnipod 5 — reportedly the same shape and size — so the defining "no tubing, no separate insulin line" advantage carries over unchanged.34 Insulin is delivered through an automatically inserted cannula, exactly as on today's Pod.5

Reservoir and wear. The Pod is expected to retain the current ~200-unit U-100 reservoir and roughly three-day (72-hour) single-use wear; a larger redesign with more insulin capacity and longer wear is described by Insulet as a later step planned for beyond 2028, not part of the initial Omnipod 6.3 As with every Insulet Pod, the whole unit is replaced each change — there is no durable pump body.5

Occlusion detection and reliability. Omnipod 6 inherits Insulet's mature on-body Pod platform, including its occlusion monitoring and alarms.5 Because it is pre-market, it has no real-world track record yet, but the pivotal STRIVE trial (132 participants: 98 with type 1 and 34 with type 2 diabetes, ages 2–70) reported non-inferior hypoglycemia versus Omnipod 5 and no cases of diabetic ketoacidosis or severe hypoglycemia.46 In that study the new system delivered up to 50% more automated insulin and, for adults with type 1, raised time in tight range (70–140 mg/dL) to 54% versus 47% and time in range (70–180 mg/dL) to 77% versus 73%.4

Which CGMs and algorithms it works with. The headline change is a single "universal" Pod designed to work across Dexcom and FreeStyle Libre sensors — and future CGMs — instead of separately manufactured CGM-specific Pods, which Insulet says will also let it ship updates six to nine months faster.13 It is paired with a fully new adaptive-learning algorithm that learns each user's insulin needs (with particular benefit for people who bolus less often) and lowers the glucose target to 100 mg/dL (5.6 mmol/L), down from 110 mg/dL on Omnipod 5.13 It remains a hybrid closed-loop, so you still announce meals; it is a closed commercial system and does not support DIY/open-source loops.2

Phone bolusing. Insulet describes a redesigned app and controller experience aimed at simpler setup and daily use; full smartphone bolusing — the standard on Omnipod 5 — is expected to continue, with a dedicated controller still offered.13

Access and cost by region. None yet. The device is investigational: Insulet plans a 510(k) submission to the FDA and is targeting a 2027 US launch, with the STRIVE 2 comparative study (NCT07579702) recruiting at the time of writing.27 Regional rollout beyond the US, age clearances, and per-Pod pricing are all unconfirmed.

What's coming. Insulet positions Omnipod 6 as a software- and connectivity-led upgrade that sets up a bigger hardware redesign — more insulin, extended wear, and eventually fully closed-loop algorithms — slated for beyond 2028.3 In parallel, Insulet is developing a separate fully closed-loop system for type 2 diabetes that requires no meal entry, supported by the EVOLVE pivotal trial, with a 510(k) filing planned for 2027 and a launch targeted for 2028.42

References

  1. Insulet Corporation. Insulet Outlines Long-Term Strategy at 2025 Investor Day — Omnipod 6 intended for 2027 with an adaptive-learning algorithm, a single universal Pod across all CGM systems, stronger Bluetooth, and a new architecture enabling innovations 6–9 months faster (Nov 20, 2025). As reported by MedTech Dive. https://www.medtechdive.com/news/insulet-patch-pump-plans/806292/ ↩ ↩2 ↩3 ↩4

  2. Park A (MedTech Dive). Insulet unveils plans for new diabetes devices — Omnipod 6 to be a hybrid closed-loop, 2027 launch, STRIVE study fully enrolled with 510(k) filing expected, connecting with all major CGMs including Abbott's Libre 3 Plus. https://www.medtechdive.com/news/insulet-patch-pump-plans/806292/ ↩ ↩2 ↩3 ↩4

  3. Diabetech. Omnipod 6 Is Coming in 2027 — Here's Everything We Know — expected 200-unit reservoir, three-day wear, same shape and size, one universal Pod for Dexcom/Libre/future CGMs, lower 100 mg/dL target, redesigned app and controller; larger redesign planned for beyond 2028. https://www.diabetech.info/p/omnipod-6-is-coming-in-2027-here-s-everything-we-know ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  4. Insulet Corporation. Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems — STRIVE pivotal trial (n=132; 98 type 1, 34 type 2; ages 2–70), 100 mg/dL target, up to 50% more automated insulin, time in tight range 54% vs 47% and time in range 77% vs 73% for type 1 ≥14 y, non-inferior hypoglycemia, no DKA/severe hypoglycemia; presented at the ADA 86th Scientific Sessions (June 6, 2026). https://www.biospace.com/press-releases/insulet-reveals-new-data-supporting-breakthrough-omnipod-6-and-fully-closed-loop-aid-systems-designed-to-improve-outcomes-reduce-effort-and-unlock-barriers-to-care ↩ ↩2 ↩3 ↩4

  5. Insulet (Omnipod). Simplify Life with Omnipod 5 — product overview — predecessor reference for carried-over hardware: tubeless waterproof Pod, up to 200 U of U-100 insulin, automatic cannula insertion, ~72 h single-use wear. https://www.omnipod.com/what-is-omnipod/omnipod-5 ↩ ↩2 ↩3

  6. Hospital Management. Insulet reports new data for Omnipod 6 and FCL systems — corroborates STRIVE participant numbers, time-in-range gains, bolus reduction, and safety (June 2026). https://www.hospitalmanagement.net/news/insulet-new-data-omnipod-6-fcl-2/ ↩

  7. ClinicalTrials.gov. Efficacy of the Omnipod 6 System Compared With the Omnipod 5 System in Individuals With Type 1 or Type 2 Diabetes and Suboptimal Glycemia (STRIVE 2; NCT07579702) — Insulet-sponsored randomized crossover study, Omnipod 6 vs Omnipod 5, recruiting. https://clinicaltrials.gov/study/NCT07579702 ↩

Coming soon

ETA · 510(k) filing planned; targeted 2027 US launch (not yet FDA-cleared)

  • →510(k) FDA submission · planned (ahead of 2027 launch)
  • →US launch as Omnipod 5 successor with adaptive-learning algorithm, lower 100 mg/dL target, and one universal Pod across Dexcom/Libre · 2027
  • →Larger hardware redesign: more insulin capacity, longer wear, fully closed loop · beyond 2028
  • →Separate Insulet fully closed-loop type 2 system (EVOLVE trial; 510(k) filing 2027) · launch targeted 2028

Sources

  1. [1]Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day (Omnipod 6 in 2027: adaptive-learning algorithm, universal Pod, stronger Bluetooth, faster innovation architecture) · news · 2025-11-20
  2. [2]Insulet unveils plans for new diabetes devices (Omnipod 6 hybrid closed-loop, 2027 launch, STRIVE study, all-major-CGM compatibility) · news · 2025-11-21
  3. [3]Omnipod 6 Is Coming in 2027 — Here's Everything We Know (200-unit reservoir, 3-day wear, same shape/size, one universal Pod for Dexcom and Libre, 100 mg/dL target, redesigned app and controller) · news
  4. [4]Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems (STRIVE pivotal trial, ADA 86th Scientific Sessions, June 2026) · manufacturer · 2026-06-06
  5. [5]Efficacy of the Omnipod 6 System Compared With the Omnipod 5 System in Individuals With Type 1 or Type 2 Diabetes (STRIVE 2; NCT07579702) · registry
  6. [6]Insulet reports new data for Omnipod 6 and FCL systems · news · 2026-06-08
  7. [7]Simplify Life with Omnipod 5 — product overview (tubeless waterproof Pod, up to 200 U, ~72 h wear) — predecessor reference for carried-over hardware · manufacturer